Update on Clinical Trials for Nonalcoholic Steatohepatitis

Abstract: Tremendous effort has been put forth over the past 2 decades in understanding the pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Although multiple potential […]

Nonalcoholic Steatohepatitis Drug Development

Worldwide, the most common cause of chronic liver disease is now nonalcoholic fatty liver disease, which affects a quarter of the population. This disease is a […]

Drug Development for the Management of Nonalcoholic Steatohepatitis Cirrhosis

G&H  What is the prevalence of cirrhosis in patients who have nonalcoholic steatohepatitis? NA  Cirrhosis, or stage 4 fibrosis, is the last stage of the histologic […]

Genetics of Nonalcoholic Steatohepatitis

  G&H  What are the main genes involved with nonalcoholic steatohepatitis? AS  There are a growing number of genes that have been linked both to the […]

Highlights in Nonalcoholic Steatohepatitis (NASH) From Digestive Disease Week 2020

A Review of Selected Presentations From DDW 2020   Obeticholic Acid Improves Experimental Non-Invasive Markers of Non-Alcoholic Steatohepatitis and Advanced Fibrosis: Results of a Secondary Analysis […]

Noninvasive Tests (NITs) in the Management of Nonalcoholic Steatohepatitis (NASH)

  Abstract: Nonalcoholic fatty liver disease (NAFLD) affects approximately a quarter of the adult population in most Western countries, particularly those in Europe and North America. […]

Current Understanding of Risk for Nonalcoholic Steatohepatitis and Progressive Fibrosis

  G&H  What is the natural history of nonalcoholic steatohepatitis? MN  Nonalcoholic steatohepatitis (NASH) is part of the disease spectrum of nonalcoholic fatty liver disease (NAFLD). […]

The Future of Treatment for Nonalcoholic Steatohepatitis

  G&H  How has nonalcoholic steatohepatitis traditionally been treated? MC  No therapies have yet been approved by the US Food and Drug Administration (FDA) for the […]

Lifestyle Interventions Beyond Diet and Exercise for Patients With Nonalcoholic Fatty Liver Disease

  Abstract: Nonalcoholic fatty liver disease (NAFLD) is a growing worldwide concern, affecting approximately 30% of the US adult population. Developing pharmacologic therapies for NAFLD is […]

Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic

  Abstract: Nonalcoholic fatty liver disease (NAFLD) is a spectrum of diseases ranging from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH) to advanced fibrosis and cirrhosis […]

Emerging Research on MGL-3196 for the Treatment of Nonalcoholic Steatohepatitis

  G&H  What is the mechanism of action of MGL-3196? ZY  MGL-3196 (Madrigal Pharmaceuticals) is a thyroid hormone receptor β agonist. Thyroid hormone receptors can be […]

Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

  Abstract: Nonalcoholic fatty liver disease (NAFLD) affects 75 to 100 million adults in the United States and is the leading cause of chronic liver disease […]

Pharmacologic Management of Nonalcoholic Steatohepatitis

  Abstract: Nonalcoholic steatohepatitis (NASH) is increasingly recognized as a major form of chronic liver disease in adults and children. Although improved dietary habits and regular […]

Overview of Current and Emerging Therapeutic Approaches to Nonalcoholic Steatohepatitis 

  G&H  What role do diet and exercise play in the treatment of nonalcoholic steatohepatitis? SH  Diet and exercise are the cornerstone of therapy for patients […]

Risk of Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis

  G&H  How common are nonalcoholic steatohepatitis and hepatocellular carcinoma in the United States, and how often do they coexist in a patient? MC  Fatty liver […]

Gastro-Hep News

Inflammatory Bowel Disease Associated With Increased Risk of Myocardial Infarction Patients with inflammatory bowel disease (IBD), particularly women and patients between ages 20 to 25 years, […]

Gastro-Hep News

Committee for Medicinal Products for Human Use Votes for 8-Week Treatment Option for Hepatitis C Virus Infection On February 28, 2017, the Committee for Medicinal Products […]

Millennium Medical Publishing, Inc
https://botbot.com.tr/ situs slot toto slot toto slot toto apktogel rp888 situs slot gacor maxwin https://es.sumal.com/ https://injectcare.com/ toto slot toto slot slot 4d situs toto slot 4d slot gacor 4d toto slot slot gacor slot online gacor toto slot https://cincindepok.com/contact/ situs togel PEWE4D Depobos toto slot slot gacor 4d situs toto slot gacor https://bezgluten.net/zivotinje/vodeni-svet-zivotinja/glavne-vrste-morskih-riba toto slot RP888 toto CONGOR4D amatogel situs togel naruto 88 toto slot slot deposit dana slot 4d slot 4d situs toto toto slot apk slot tribun62 rp888 JHONBET77 tribun62 cheat slot toto slot kepo66 slot 4d slot 4d pajaktoto login pajaktoto login